zenocutuzumab
merus
['solid tumor', 'zenocutuzumab']
one of my favorite talks this #asco22 was by dr. , who shared an impressive update on the safety &amp; activity of zenocutuzumab (her2-her3 bispecific ab) in nrg1-fusion+ solid tumors. orr: 34% (27/79) &amp; 42% (8/19) in pdac. well-tolerated w/ a median dor was 9.1 mo. 
Heme/Onc Fellow @StanfordCancer | IM @StanfordMedRes (‘20)??????? MD @CleClinicLCM (‘18)???????| Views my own.